<![CDATA[Paxalisib Achieves 100% Clinical Benefit Rate in Metastatic TNBC]]>

Data ReadoutpositivePaxalisibPositive

AI Analysis

Summary

Paxalisib demonstrated a 100% clinical benefit rate and 83% objective response rate in patients with metastatic triple-negative breast cancer. The positive data supports continued development of the drug for this indication.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

100% clinical benefit rate and 83% objective response rate in metastatic TNBC

Importance:6/10

Sentiment:

0.85

oncologybreast cancertriple-negativeclinical trialefficacy

Read the original article

Published by Cancer Network on August 28, 2026 5:00 PM

Read Original